Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery

Binbin Chen, Russ B. AltmanOrphanet 2017 · DOI

TL;DR

Developing treatments for rare genetic diseases is a major challenge, with only a small fraction having approved drugs. This paper presents a computational pipeline to identify promising rare genetic diseases for drug development, focusing on those with gain-of-function mutations or loss-of-function mutations amenable to allosteric activation. Their analysis reveals significant gaps in current FDA orphan drug coverage and suggests prioritizing these specific disease types for future therapeutic efforts.

What Problem Does This Paper Address?

The development of effective treatments for rare genetic diseases is hampered by several factors, including limited market size and high development costs. Despite incentives like the Orphan Drug Act, a vast majority of the estimated 7,000 rare diseases lack any FDA-designated drug. While advances in next-generation sequencing have accelerated the identification of disease-causing genetic mutations, translating this knowledge into therapies remains a bottleneck. This paper aims to address this by systematically identifying rare genetic diseases that are more amenable to drug development, thereby guiding research and investment towards the most promising targets.

Methods

The authors developed a computational pipeline to identify potential drug targets for rare genetic diseases. This pipeline leverages natural language processing and human curation to mine the Online Mendelian Inheritance in Man (OMIM) database. The core strategy involves two parallel branches:

  1. Gain-of-Function Mutations: Diseases caused by gain-of-function mutations are prioritized if they have:
  2. A single, well-characterized gain-of-function mutation.
  3. Late or adult onset, allowing a larger therapeutic window.
  4. A solved crystal structure for the affected protein, enabling rational drug design (specifically for inhibitors).
  5. Loss-of-Function Mutations with Allosteric Activation: Diseases caused by loss-of-function mutations are considered if there are known allosteric activators that can restore protein function. This requires:
  6. A solved crystal structure for the affected protein.
  7. Identification of known allosteric activators from databases like the Allosteric Database (ASD).

The pipeline filters OMIM entries based on these criteria, and the final candidate list is manually verified.

Datasets

  • Online Mendelian Inheritance in Man (OMIM) database: Used as the primary source for disease and gene information, including mutation types and descriptions. Data was downloaded in June 2015.
  • FDA Orphan Drug List: Used to assess current treatment coverage and identify trends in drug development. Data was obtained from the FDA website in July 2015.
  • Allosteric Database (ASD): Used to identify known allosteric activators for loss-of-function mutations.
  • Comparative Toxicogenomics Database (CTD): Used to map orphan drug treatment descriptions to disease categories.

Key Insights and Ideas

  • Uneven Drug Coverage: The current FDA orphan drug landscape shows a significant disparity in coverage across different rare disease categories. While neurological disorders and genetic diseases are common, they are underrepresented compared to cancers.
  • Gain-of-Function as a Promising Target Type: Diseases caused by gain-of-function mutations appear to be more readily targeted by drugs. This is supported by the observation that these diseases have a higher percentage of FDA-designated orphan drugs compared to all rare diseases or Mendelian diseases in general.
  • Allosteric Activation as a Key Strategy: For loss-of-function mutations, the identification of known allosteric activators is crucial. This approach offers a viable pathway for developing therapies where direct restoration of function is difficult.
  • Importance of Solved Protein Structures: The availability of solved protein crystal structures is a critical factor for both rational inhibitor design (for gain-of-function) and for understanding allosteric mechanisms (for loss-of-function).
  • Trinucleotide Repeat Disorders: A significant portion of the identified gain-of-function candidates are caused by long trinucleotide repeats, highlighting this as a particularly important class of rare diseases for targeted drug development.

Key Results

  • The authors identified 34 rare genetic diseases as promising candidates for drug development using their pipeline.
  • Only 8% of all rare diseases have an FDA-designated orphan drug.
  • 16-18% of targeted diseases by orphan drugs fall into the genetic disease category, despite genetic diseases comprising over 60% of known rare diseases.
  • 12% of gain-of-function Mendelian diseases have a designated orphan drug, increasing to 16% when further filtered for adult-onset diseases.
  • Table 1 lists 39 gain-of-function mutation candidates, grouped by molecular mechanism (e.g., over-activation, gene duplication, trinucleotide repeats).
  • Table 2 lists 14 loss-of-function mutation candidates with known allosteric activators.

Limitations and Future Work

  • Scope Limitation: The pipeline focuses on diseases caused by single mutations and requires solved protein structures, which limits the scope of the analysis. Diseases with complex genetic etiologies or proteins without solved structures are not included.
  • Manual Curation: While NLP is used, manual curation is still employed, which can be time-consuming and potentially introduce human bias.
  • Upstream/Downstream Effectors: The current analysis targets driver mutations directly. The authors suggest that examining upstream regulators and downstream effectors could reveal additional therapeutic opportunities.
  • Drug Repurposing: The authors note that drug repurposing is a significant route for orphan drug development and suggest that their identified disease targets can be screened against existing FDA-approved drugs.
  • Integration with Research Platforms: The results can be integrated with broader rare disease research platforms like RD-Connect and Orphanet to foster interdisciplinary collaboration.

Summary updated

Abstract

Our analysis has revealed uneven coverage of rare diseases in the current US FDA orphan drug space. Diseases with gain-of-function mutations or loss-of-function mutations and known allosteric activators should be prioritized for drug treatments.
BibTeX
@inproceedings{chen2017opportunities,
  author = {Binbin Chen and Russ B. Altman},
  title = {{Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery}},
  booktitle = {Orphanet},
  year = {2017},
  doi = {10.1186/s13023-017-0614-4},
}
Figure